Dosing and Administration

CINQAIR is the first and only intravenous (IV) therapy approved for adult
patients with severe asthma and an eosinophilic phenotype

HCP-controlled IV administration at home, in an office, or at an infusion center1

  • HCP administration in each infusion setting helps ensure consistent dosing and administration
  • Dosing schedule and IV administration enable severe asthmatic patients to have monthly contact with an HCP
    • IV doses of 3 mg/kg once every 4 weeks
  • Administered by an HCP in as little as 20-50 minutes*
  • An option for patients who cannot or do not want to self-inject
  • Provides visibility to delayed or missed doses
  • 100% bioavailability1,2

HCP=healthcare professional.

*Monitor patients during the infusion and for an appropriate time afterward.1

The only anti–IL-5 that offers personalized, weight-based dosing with
HCP-controlled administration

Use the Dosing Calculator to quickly determine the appropriate weight-based dose of
CINQAIR for your patient. You can also download a Dosing PDF.

CINQAIR Dose Volume of CINQAIR Solution

CINQAIR is given in weight-based doses1

  • Personalized, weight-based IV infusion:

    • IV doses of 3 mg/kg every 4 weeks1

  • Administration time of 20-50 minutes:

    • Monitor patients during the infusion and for an appropriate time afterward1

  • Single-use vials:

    • 100 mg/10 mL solution ready for dilution and IV administration1

  • Incidence of administration-site reactions was similar between CINQAIR 3.0 mg/kg (2%) and placebo (2%)3:

    • None were severe in intensity, serious, or resulted in discontinuation of treatment

  • Refrigeration required:

    • Store in refrigerator at 36°F to 46°F (2°C to 8°C)1

  • Storage required if not used immediately after preparation:

    • Store in refrigerator or at room temperature up to 77°F (25°C), protected from light, for up to 16 hours1

  • Shelf life of a vial of CINQAIR:

    • 36 months from the date of manufacturing if stored according to the package insert and above4
    • See vial and product package for the expiration date4

REFERENCES: 1. CINQAIR Prescribing Information. West Chester, PA. Teva Respiratory, LLC. 2. Cyriac JM, James E. Switch over from intravenous to oral therapy: a concise overview. J Pharmacol Pharmacother. 2014;5(2):83-87. 3. Data on file (Clinical Study Report: Summary of Clinical Safety). Parsippany, NJ: Teva Respiratory, LLC. 4. Data on file (United States Food and Drug Administration Letter. Biologics License Application Approval). Parsippany, NJ: Teva Respiratory, LLC. March 2016.